The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52443 | DBCO-PEG4-GGFG-Dxd | 2694856-51-2 | DBCO-PEG4-GGFG-Dxd is part of an antibody-active molecule conjugate, consisting of the DNA topoisomerase I inhibitor Dxd and the cleavable ADC (Antibody-drug conjugate) linker DBCO-PEG4-GGFG. |
|
V51228 | DBCO-PEG4-MMAF | 2360411-65-8 | drug-linker conjugate |
|
V76164 | DBCO-PEG4-VA-PBD | 2241644-09-5 | DBCO-PEG4-VA-PBD is an antibody-drug-conjugate/ADC, which is made up of the anti-tumor antibiotic Pyrrolobenzodiazepine (PBD) and DBCO-PEG4-VA. |
|
V51230 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | drug-linker conjugate |
|
V51215 | DBCO-PEG4-VC-PAB-DMEA-PNU-159682 | 2259318-56-2 | drug-linker conjugate for ADC |
|
V53308 | DBCO-PEG4-VC-PAB-MMAE | 2129164-91-4 | DBCO-PEG4-VC-PAB-MMAE consists of ADC Linker (DBCO-PEG4-VC-PAB) and tubulin polymerization inhibitor MMAE. |
|
V51225 | DBM-MMAF | 1810001-93-4 | drug-linker conjugate |
|
V4653 | Deruxtecan | 1599440-13-7 | Deruxtecan (DS-8201a; DS8201a; exatecan analog; DX-8951 analog), a drug-linker conjugate for antibody-drug conjugate (ADC, Patritumab deruxtecan orU3-1402), is a novel, potent toxin and linker moiety of DS-8201. |
|
V79085 | Desmethyl Vc-seco-DUBA | Desmethyl Vc-seco-DUBA is made up of cleavable ADC (Antibody-drug conjugate) linker (Desmethyl Vc-seco) and DUBA, a DNA alkylating agent. | |
|
V54760 | DGN549-C | 2058075-34-4 | DGN549-C consists of the cleavable ADC (Antibody-drug conjugate) linker valine-alanine (va) and a PBD dimer. |
|
V54776 | DGN549-L | 1884276-68-9 | DGN549-L contains a cleavable ADC?linker and a DNA alkylating agent for antibody conjugation of lysine residues. |
|
V54782 | DL-01 | 2821770-49-2 | DL-01 is an ADC active molecule-linker conjugate (drug-linker conjugates for ADC) that can be used for the synthesis of ADC. |
|
V54773 | DM4-SMCC | 1228105-52-9 | DM4-SMCC is an antibody-linker conjugate for ADC with anti-tumor activity. |
|
V54772 | DM4-SPDP | 2245698-48-8 | DM4-SPDP is made up of linker SPDP and toxic molecule DM4, and may be utilized to prepare antibody-drug-conjugates/ADCss. |
|
V20208 | Doxorubicin-SMCC | 400647-59-8 | Doxorubicin-SMCC (dox-SMCC); ADR-SMCC) is a doxorubicin analog used as drug-linker conjugate for the synthesis of antibody-drug-conjugates (ADC). |
|
V79474 | Fmoc-Gly3-VC-PAB-MMAE | Fmoc-Gly3-VC-PAB-MMAE is an ADC drug-linker conjugates (Drug-Linker Conjugates for ADC). | |
|
V77005 | Fmoc-Val-Cit-PAB-DuocarmycinTM | Fmoc-Val-Cit-PAB-Duocarmycin TM is an antibody-linker conjugate for ADC, which is made up of anti-tumor antibiotic Duocarmycin TM and Fmoc-Val-Cit-PAB. | |
|
V54796 | Fmoc-VAP-MMAE | 1912408-91-3 | Fmoc-VAP-MMAE is an ADC drug-linker conjugate. |
|
V53016 | GGFG-amide-glycol-amide-Exatecan | 2866301-18-8 | GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan analogue that may be utilized in the preparation /synthesis of antibody drug conjugates (ADCs). |
|
V53401 | GGFG-Eribulin | 2841688-66-0 | GGFG-Eribulin (Compound GGFG) is an ADC-Drug-Linker Conjugates for ADC. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
